Pros and cons for C4d as a biomarker

Kidney International

Volumn 81, Issue 7, 2012, Pages 628-639

  Cohen, Danielle ^a   Colvin, Robert B ^b   Daha, Mohamed R ^a   Drachenberg, Cinthia B ^c   Haas, Mark ^d   Nickeleit, Volker ^e   Salmon, Jane E ^f   Sis, Banu ^g   Zhao, Ming Hui ^h   Bruijn, Jan A ^a   Bajema, Ingeborg M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d Cedars Sinai Medical Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h PEKING UNIVERSITY   (China)

Author keywords

acute allograft rejection; chronic rejection; complement; transplant pathology; transplantation

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4D;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNITY; CELL DAMAGE; CHRONIC GRAFT REJECTION; COVALENT BOND; DISEASE MARKER; HEART TRANSPLANTATION; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; LUNG TRANSPLANTATION; NONHUMAN; PANCREAS TRANSPLANTATION; PREGNANCY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; REVIEW;

EID: 84858333295     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.497     Document Type: Review

References (88)

1. Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 2232-2239.
2. Sarma JV, Ward PA. The complement system. Cell Tissue Res 2011; 343: 227-235.
3. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15: 42-48.
4. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
5. Berger SP, Roos A, Daha MR. Complement and the kidney: What the nephrologist needs to know in 2006? Nephrol Dial Transplant 2005; 20: 2613-2619.
6. Daha MR, van Kooten C, Roos A. Compliments from complement: A fourth pathway of complement activation? Nephrol Dial Transplant 2006; 21: 3374-3376.
7. Williams GM, Hume DM, Hudson RP et al. 'Hyperacute' renal-homograft rejection in man. N Engl J Med 1968; 279: 611-618.
8. Kissmeyer-Nielsen F, Olsen S, Petersen VP et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966; 2: 662-665.
9. Porter KA. Morphological aspects of renal homograft rejection. Br Med Bull 1965; 21: 171-175.
10. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
11. Feucht HE, Felber E, Gokel MJ et al. Vascular deposition of complementsplit products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464-470.
12. Feucht HE, Lederer SR, Kluth B. Humoral alloreactivity in recipients of renal allografts as a risk factor for the development of delayed graft function. Transplantation 1998; 65: 757-758.
13. Kluth-Pepper B, Schneeberger H, Lederer SR et al. Impact of humoral alloreactivity on the survival of renal allografts. Transplant Proc 1998; 30: 1772.
14. Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
15. Herzenberg AM, Gill JS, Djurdjev O et al. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241.
16. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
17. Crespo-Leiro MG, Veiga-Barreiro A, Domenech N et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): Incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005; 5: 2560-2564.
18. de Kort H, Munivenkatappa RB, Berger SP et al. Pancreas allograft biopsies with positive c4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1660-1667.
19. Fedrigo M, Gambino A, Tona F et al. Can C4d immunostaining on endomyocardial biopsies be considered a prognostic biomarker in heart transplant recipients? Transplantation 2010; 90: 791-798.
20. Glanville AR. Antibody-mediated rejection in lung transplantation: Myth or reality? J Heart Lung Transplant 2010; 29: 395-400.
21. Magro CM, Pope HA, Klinger D et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant 2003; 3: 1143-1154.
22. Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983.
23. Lucas JG, Co JP, Nwaogwugwu UT et al. Antibody-mediated rejection in kidney transplantation: An update. Expert Opin Pharmacother 2011; 12: 579-592.
24. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681-686.
25. Wahrmann M, Haidinger M, Kormoczi GF et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385-1390.
26. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277-284.
27. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
28. Bohmig GA, Exner M, Habicht A et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.
29. Smith RN, Kawai T, Boskovic S et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008; 8: 1662-1672.
30. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804-2812.
31. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: Results of a 2-year prospective trial. Transplantation 2005; 80: 1194-1197.
32. Worthington JE, Martin S, Al-Husseini DM et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034-1040.
33. Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
34. Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058-2066.
35. Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 2409-2418.
36. Vongwiwatana A, Gourishankar S, Campbell PM et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4: 124-129.
37. Sis B, Jhangri GS, Bunnag S et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312-2323.
38. Loupy A, Suberbielle-Boissel C, Hill GS et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561-2570.
39. Loupy A, Hill GS, Suberbielle C et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56-65.
40. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: Correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011.
41. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9: 2459-2465.
42. Lee CY, Lotfi-Emran S, Erdinc M et al. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation 2007; 84: 1324-1334.
43. Uehara S, Chase CM, Kitchens WH et al. NK cells can trigger allograft vasculopathy: The role of hybrid resistance in solid organ allografts. J Immunol 2005; 175: 3424-3430.
44. Hirohashi T, Chase CM, Della Pelle P et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant; e-pub ahead of print 9 November 2011.
45. Hidalgo LG, Sis B, Sellares J et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10: 1812-1822.
46. Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887-895.
47. Uchida K, Tominaga Y, Haba T et al. ABO-incompatible renal transplantation-dissociation of ABO antibodies. Transplant Proc 1998; 30: 2302-2303.
48. Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibodymediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4: 101-107.
49. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711-717.
50. Kanetsuna Y, Yamaguchi Y, Horita S et al. C4d and/or immunoglobulins deposition in peritubular capillaries in perioperative graft biopsies in ABO-incompatible renal transplantation. Clin Transplant 2004; 18(Suppl 11): 13-17.
51. Toki D, Ishida H, Setoguchi K et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: Long-term impact and risk factors. Am J Transplant 2009; 9: 567-577.
52. Haas M, Rahman MH, Racusen LC et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6: 1829-1840.
53. Haas M, Segev DL, Racusen LC et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol 2009; 20: 197-204.
54. Park WD, Grande JP, Ninova D et al. Accommodation in ABOincompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3: 952-960.
55. Haas M. The significance of C4d staining with minimal histologic abnormalities. Curr Opin Organ Transplant 2010; 15: 21-27.
56. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
57. Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. J Heart Transplant 1989; 8: 430-443.
58. Lones MA, Czer LS, Trento A et al. Clinical-pathologic features of humoral rejection in cardiac allografts: A study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151-162.
59. Fedson SE, Daniel SS, Husain AN. Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation. J Heart Lung Transplant 2008; 27: 372-379.
60. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720.
61. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464-471.
62. Ionescu DN, Girnita AL, Zeevi A et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005; 15: 63-68.
63. Magro CM, Deng A, Pope-Harman A et al. Humorally mediated posttransplantation septal capillary injury syndrome as a common form of pulmonary allograft rejection: A hypothesis. Transplantation 2002; 74: 1273-1280.
64. Wallace WD, Reed EF, Ross D et al. C4d staining of pulmonary allograft biopsies: An immunoperoxidase study. J Heart Lung Transplant 2005; 24: 1565-1570.
65. Magro CM, Ross P, Kelsey M et al. Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant 2003; 3: 1155-1166.
66. Westall GP, Snell GI, McLean C et al. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008; 27: 722-728.
67. Zwirner J, Felber E, Herzog V et al. Classical pathway of complement activation in normal and diseased human glomeruli. Kidney Int 1989; 36: 1069-1077.
68. Zwirner J, Felber E, Burger R et al. Classical pathway of complement activation in mammalian kidneys. Immunology 1993; 80: 162-167.
69. Chen M, Xing GQ, Yu F et al. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009; 24: 1247-1252.
70. Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun 2010; 34: J276-J286.
71. Cohen D, Koopmans M, Kremer Hovinga I et al. Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum 2008; 58: 2460-2469.
72. Kusunoki Y, Itami N, Tochimaru H et al. Glomerular deposition of C4 cleavage fragment (C4d) and C4-binding protein in idiopathic membranous glomerulonephritis. Nephron 1989; 51: 17-19.
73. Xing GQ, Chen M, Liu G et al. Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. J Clin Immunol 2010; 30: 144-156.
74. Kim SH, Jeong HJ. Glomerular C4d deposition indicates in situ classic complement pathway activation, but is not a marker for lupus nephritis activity. Yonsei Med J 2003; 44: 75-80.
75. Shen Y, Chen XW, Sun CY et al. Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases. Lupus 2010; 19: 1195-1203.
76. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523.
77. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
78. Medawar PB. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol 1953; 7: 320-338.
79. Hiby SE, Apps R, Sharkey AM et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010; 120: 4102-4110.
80. Burton GJ, Jauniaux E. Placental oxidative stress: From miscarriage to preeclampsia. J Soc Gynecol Investig 2004; 11: 342-352.
81. Branch DW, Gibson M, Silver RM. Clinical practice. Recurrent miscarriage. N Engl J Med 2010; 363: 1740-1747.
82. Ruiz-Irastorza G, Crowther M, Branch W et al. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
83. Cohen D, Berger SP, Steup-Beekman GM et al. Diagnosis and management of the antiphospholipid syndrome. Br Med J 2010; 340: C2541.
84. Rote NS, Vogt E, DeVere G et al. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol 1998; 39: 125-136.
85. Cohen D, Buurma A, Goemaere NN et al. Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011; 225: 502-511.
86. Shamonki JM, Salmon JE, Hyjek E et al. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007; 196: 167-165.
87. Salmon JE, Heuser C, Triebwasser M et al. Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8: E1001013.
88. Lee J, Romero R, Xu Y et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: Chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One 2011; 6: E16806.